# Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

> **NCT00799747** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD4017
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00799747
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** —
- **Final completion:** 2009-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2009-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00799747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00799747, "Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00799747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*